Publications by authors named "S Galluzzo"
Drug development for children presents unique challenges and is highly regulated. Novel approaches, such as the use of extrapolation to address, for example, the need to avoid unethical studies, whilst supporting robust evidence generation have been developed in support of benefit/risk considerations by regulatory authorities. This is only one step in the decision-making process towards access, which in Europe also includes health technology assessment (HTA) bodies.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates treatment patterns for Systemic Lupus Erythematosus (SLE) in both adults and children, highlighting the lack of real-world data on medication use, particularly in childhood-onset SLE (cSLE).
- Researchers analyzed data from over 11,000 SLE patients across multiple European countries, finding that the majority were female, with specific first-line treatments being hydroxychloroquine and glucocorticoids for both demographics.
- The findings indicate that while adult treatment aligns with guidelines, the high use of glucocorticoids in children suggests a need for alternatives and specialized treatment recommendations for pediatric patients.
Background: Non-convulsive status epilepticus (NCSE) is a time-dependent neurological disorder often misdiagnosed in the emergency setting. Electroencephalography (EEG) is often not available on a 24/7 basis, and Salzburg criteria may at times miss the diagnosis. Here, we tested the accuracy of hyperperfusion on CT perfusion imaging (CTP) in the identification of NCSE against Salzburg criteria, to define its potential role in a pragmatic diagnostic workflow.
View Article and Find Full Text PDFIntroduction: Medium vessel occlusion (MeVO) accounts for 30% of acute ischemic stroke cases. The risk/benefit profile of endovascular thrombectomy (EVT) and intravenous thrombolysis (IVT) or the combination of the two (bridging therapy (BT)) is still unclear in MeVO. Here, we compare reperfusion strategies in MeVO for clinical and radiological outcomes.
View Article and Find Full Text PDFArticle Synopsis
- DNA damage response inhibitors could be really helpful in treating childhood cancers, but we still need to figure out the best way to use them and who should get them.
- There aren't many kids with cancer to test these drugs, which makes it tricky to find the right way to prioritize their use in treatments.
- Some specific types of drugs, like CHK1 inhibitors, show promise for certain pediatric tumors and should be made available for trials quickly.